RESUMEN
One of the major targets for breast cancer therapy is the epidermal growth factor receptor (EGFR) and related receptors, which signal via different signal transduction pathways including the mitogen-activated protein kinase (MAPK) pathway. This study determined whether there is a correlation between EGFR/HER2 status and MAPK (ERK1/2) phosphorylation in breast cancer cells, and how this affects the response to an inhibitor of the receptors. Expression of EGFR, HER2 and phosphorylated ERK1/2 were measured by immunoblotting in a panel of breast cancer cell lines. Several lines expressed high levels of pERK1/2, with no obvious correlation with the level of EGFR/HER2. The EGFR tyrosine kinase inhibitor PKI166 inhibited growth and induced apoptosis in some cells with high levels of growth factor receptors (MDA-MB-468, SUM149, SKBR3), but was less effective in cells that also had high basal ERK1/2 activity (MDA-MB-231). The combination of an inhibitor of MAPK signalling (U0126) and PKI166 produced significantly more inhibition and apoptosis than either agent alone. This suggests that constitutive activation of the MAPK pathway may bypass inhibition of EGFR/HER2 tyrosine kinases, and lead to insensitivity to agents targeting the receptors. However, inhibiting both EGFR/HER2 and MAPK signalling can result in significant growth inhibition and apoptosis of EGFR-expressing breast cancer cells.
Asunto(s)
Apoptosis , Neoplasias de la Mama/genética , Neoplasias de la Mama/fisiopatología , Receptores ErbB/metabolismo , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Metástasis de la Neoplasia/fisiopatología , Femenino , Genes erbB-2 , Humanos , Immunoblotting , Proteína Quinasa 3 Activada por Mitógenos , Fosforilación , Transducción de Señal , Células Tumorales CultivadasRESUMEN
The gene for HER2/neu is overexpressed in 30-40% of breast and ovarian cancers, and this overexpression correlates with increased metastasis and poor prognosis. The HER2/neu gene product, a transmembrane protein kinase member of the EGF receptor family, has significant potential as a tumor antigen for vaccination. We inserted the sequence for neu into a novel plasmid called ELVIS containing a Sindbis virus replicon that reproduces multiple copies of mRNA. Mice vaccinated one time intramuscularly demonstrated a strong antibody response against A2L2, a murine breast cancer cell line transfected to express neu. Vaccinated mice challenged in the mammary fatpad with A2L2 had reduced tumor incidence and reduced tumor mass compared to mice challenged with tumor cells lacking the neu insert. Intradermal vaccination was also protective and required 80% less plasmid for a similar level of protection. Vaccination reduced the incidence of lung metastasis from mammary fatpad tumors and reduced the number of lung metastases resulting from intravenous injection of A2L2 cells. Cytotoxic T lymphocytes cultures of immune spleen cells with P815-neu cells produced high levels of interferon-gamma indicating an antigen-specific Th1-type immune response resulting from the vaccination. In a spontaneous breast tumor model using neu transgenic mice, vaccination with ELVIS-neu protected against development of spontaneous breast tumors. Our preclinical data indicate that therapeutic vaccination of patients with ELVIS-neu may reduce metastasis from HER2/neu-expressing breast and ovarian tumors.
Asunto(s)
Neoplasias Pulmonares/prevención & control , Neoplasias Mamarias Experimentales/prevención & control , Receptor ErbB-2/genética , Vacunación , Vacunas de ADN/uso terapéutico , Animales , Femenino , Citometría de Flujo , Incidencia , Interferón gamma/metabolismo , Interleucina-4/metabolismo , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/secundario , Neoplasias Mamarias Experimentales/metabolismo , Neoplasias Mamarias Experimentales/patología , Ratones , Ratones Endogámicos BALB C , Ratones Transgénicos , Pruebas de Precipitina , Bazo/inmunología , Linfocitos T Citotóxicos/inmunología , TransfecciónRESUMEN
The growth of metastases is the end result of a multistep process in which cancer cells invade through basement membranes, extravasate into bloodstream or lymphatic vessels, survive transit in the circulation, arrest, and then grow in the new site (1). Tissue culture traits that reliably predict the metastatic ability of cancer cells are rare, possibly because any particular assay, for example, invasion through extracellular matrix (2), or growth in semisolid agarose (3) can evaluate only a tumor cell's ability to perform one step in the multistep process. Thus, animal models using transplantable tumors that produce a predictable number of metastases in suitable recipients are the standard test systems for analyzing the metastatic phenotype, and for evaluating the efficacy of antimetastatic agents. The discovery that tumor tissue could be xenografted into the mutant athymic "nude" mouse strain opened a new area for experimental studies with human tumor cells, including the analysis of their metastatic properties (1,4). Additional immunodeficient mouse strains are also available for human tumor experimentation. The combination of the nude and beige mutations produced athymic mice with reduced NK cell activity. The triple deficient beige (bg)/nude (nu)/xid mouse is functionally depleted of T and B cells and lack precursors of lymphokine activated killer (LAK) cells. Severe combined immune-deficient (SCID) mice, homozygous for the mutant gene scid, are severely deficient in both T and B cells (SCID mouse xenograft models of metastasis are described in Chapter 20 by Schumacher and Brooks). In comparisons of tumor take and metastasis of several human tumor cell lines in different immunodeficient mice, some differences were seen. Some cell lines produced a higher incidence of metastasis in the SCID vs nude mice (5,6). However, in another example, the incidence of metastasis of a human breast cancer cell line was lower in the triple deficient bg/nu/xid mice than in nude mice (4), suggesting that using a mouse with a more profound immunodeficiency does not guarantee that the implanted tumor cells will grow more aggressively. Ultimately, the choice of the strain will be dictated by the design of the experiment, as well as availability and expense. The procedures described in this chapter can be applied to any of the different immuno-deficient animals.
RESUMEN
Our objective was to determine the efficacy of adenoviral-mediated gene therapy with wild-type p53 or p21 in human breast cancer cells and investigate interactions with radiation and chemotherapy. Two human breast cancer cell lines, MDA-MB-231 and MDA-MB-435, both with p53 mutations, were transduced with adenoviral vectors containing wild-type p53 (Ad5CMV-p53) or p21/WAF1/Cip1 (Ad5CMV-p21), and the effects on growth were determined. Infection was combined with low-dose (1.4 - 3.7 Gy) irradiation to see if this would improve transduction efficiency and enhance numbers of cells killed. Transduction with either vector resulted in expression of p21WAF1/cip1 and growth inhibition, although Ad5CMV-p53 transduction produced greater growth inhibition than did Ad5CMV-p21. The cell lines differed in sensitivity to the vectors. The Ad5CMV-p53 vector in a multiplicity of infection (MOI) of 125 resulted in 50% to 80% inhibition of MDA-MB-231, while MOI 250 of the same vector resulted in 27% inhibition of MDA-MB-435. Infection with Ad5CMV-p21 produced modest growth inhibition in both cell lines (< or = 40% at MOI 200), although protein expression was detected at lower viral doses. Low dose gamma-irradiation (1.4 to 3.7 Gy) was used to try and improve the rate of gene transfer. Modest increases in transduction efficiency and duration of expression of a vector containing beta-galactosidase occurred in irradiated breast cancer cells. Radiation 24 hr before transduction with Ad5CMV-p53 increased the proportions of apoptotic MDA-MB-231 cells. The cells transduced with Ad5CMV-p21 were arrested in G1, yet when they were irradiated before adenoviral transduction, the overexpression of p21 protected the cells from the cytotoxic effects of the radiation. Clonogenic assays showed that Ad5CMV-p21 reduced the sensitivity of MDA-MB-231 to VP-16 and paclitaxel. Combining these drugs with Ad5CMV-p53 did not consistently or significantly decrease clonogenic survival.
Asunto(s)
Adenoviridae/genética , Neoplasias de la Mama , Ciclinas/genética , Terapia Genética , Proteína p53 Supresora de Tumor/genética , Anexina A5/análisis , Antineoplásicos/farmacología , Western Blotting , Terapia Combinada , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Ciclinas/análisis , Citomegalovirus/genética , Quimioterapia , Femenino , Citometría de Flujo , Humanos , Regiones Promotoras Genéticas , Radioterapia , Transducción Genética , Células Tumorales Cultivadas/química , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/efectos de la radiación , Proteína p53 Supresora de Tumor/análisisRESUMEN
Integrins play an important role in interactions between cells and the extracellular matrix, and thus have a potential role in metastasis. Expression levels of alpha6, beta1 and beta4 integrin sub-units were measured in a panel of human breast cancer cell lines by RT/PCR, immunoprecipitation and flow cytometry. All the lines expressed alpha6, with the highest levels in the MDA-MB-231 and MDA-MB-435 cells. These grew the most aggressively and were metastastic in nude mice. Low levels of alpha6 protein were measured in breast cancer cells that were poorly tumorigenic and non-metastatic in nude mice, and there was an inverse relationship between ER and alpha6 expression. RT/PCR revealed that all lines expressed the 2 isoforms of alpha6, with the alpha6A isoform generally more abundant than alpha6B isoform. Clones of MDA-MB-435 were isolated by sterile sorting for cells with high or low alpha6 expression, and two variants established from metastases in nude mice were found to differ in alpha6 expression. When injected into nude mice. the alpha6-high variants produced significantly more lung metastases than the alpha6-low variants. beta1was abundant in all lines, while beta4 was not detected in MDA-MB- 134 cells, and in the MDA-MB-435 cells an alternately spliced variant of beta4 was identified. Sequencing of the alternate variant revealed a novel sequence from a splicing event in the cytoplasmic tail of beta4. None of the cells with this variant mRNA expressed detectable levels of beta4 protein. Our results suggest that high alpha6 expression in human breast cancer cells is associated with tumorigenicity and metastatic potential.
Asunto(s)
Antígenos CD/metabolismo , Neoplasias de la Mama/metabolismo , Animales , Antígenos CD/genética , Secuencia de Bases , Neoplasias de la Mama/patología , Cartilla de ADN , Humanos , Integrina alfa6 , Ratones , Ratones Desnudos , Metástasis de la Neoplasia , Fenotipo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células Tumorales CultivadasRESUMEN
Telomeres, repeated DNA sequences (T2AG3)n that guard the ends of chromosomes, serve as a checkpoint for cell-cycle progression and regulate cell senescence and apoptosis. Loss of the telomeric repeats promotes genomic instability, which is the hallmark of most cancer cells. Whether this loss differs among tumor cells with malignant potential is unknown and was the goal of this study. An all-human telomeric DNA probe was used to perform fluorescence in situ hybridization (FISH) and the telomeric signals in interphase nuclei were quantitated using a computer software package. Southern blot analysis was carried out to measure terminal restriction fragment length (TRFL) in multiple cancer cell lines, including nonmetastatic and metastatic human breast, lung, prostate, colon, brain, and renal carcinomas, as well as human and murine melanoma clones and somatic cell hybrids. The metastatic capability of all cell lines, clones and somatic cell hybrids was evaluated subsequent to orthotopic implantation into nude mice. FISH preparations with telomeric DNA probes showed that the mean percent telomeric area in the metastatic nuclei was significantly greater than their nonmetastatic counterparts and Southern blotting in selected samples confirmed our findings. These data suggest that amplification of telomeres is directly correlated with invasive and metastatic potential of murine or human tumor cells.
Asunto(s)
ADN de Neoplasias/genética , Telómero , Animales , Southern Blotting , Ciclo Celular/genética , Núcleo Celular/fisiología , Sondas de ADN , Humanos , Hibridación Fluorescente in Situ , Interfase/genética , Ratones , Invasividad Neoplásica , Metástasis de la NeoplasiaRESUMEN
Poly(L-glutamic acid)-paclitaxel (PG-TXL) is a new water-soluble paclitaxel derivative that has shown remarkable antitumor activity against both ovarian and breast tumors. The purpose of this study was to test whether the antitumor efficacy of PG-TXL depends on tumor type, as is the case for paclitaxel, and to test whether paclitaxel-resistant tumors could be responsive to PG-TXL. We evaluated the therapeutic activity of PG-TXL against four syngeneic murine tumors (MCa-4, MCa-35, HCa-1, and FSa-II) inoculated i.m. into C3Hf/Kam mice, a human SKOV3ip1 ovarian tumor injected i.p. into nude mice, and a human MDA-MB-435Lung2 breast tumor grown in the mammary fat pad of nude mice. Two paclitaxel-responsive murine tumors, MCa-4 and MCa-35, showed significant growth delay with PG-TXL given as a single i.v. injection at its maximum tolerated dose of 160 mg of equivalent paclitaxel/kg or even at a lower dose of 120 mg of equivalent paclitaxel/kg. The other two murine tumors, HCa-1 and FSa-II, did not respond particularly well to either of the two agents, although significant growth delay was observed for both tumors with PG-TXL. In mice with SKOV3ip1 tumors, the median survival times for mice treated with PG alone and PG-TXL at doses of 60 or 120 mg of equivalent paclitaxel/kg were 43, 61, and 75 days, respectively; no survival difference was found between paclitaxel-treated and Cremophor vehicle-treated mice. In mice with MDA-MB-435Lung2 tumor, PG-TXL at a dose of 120 mg of equivalent paclitaxel/kg produced regression of the tumor in 50% of the animals, and in the remaining mice, micrometastases in the lung were found only in 25% of the animals. In comparison, treatment with paclitaxel at 60 mg/kg did not result in tumor regression, and the rate of lung metastases was 42%. These results clearly demonstrate that PG-TXL has significant therapeutic activity against breast and ovarian tumors tested in this study. Future studies to elucidate the mechanism of action of PG-TXL and to assess its clinical applications are warranted.
Asunto(s)
Neoplasias Experimentales/tratamiento farmacológico , Paclitaxel/análogos & derivados , Taxoides , Animales , Carcinoma Hepatocelular/tratamiento farmacológico , Evaluación Preclínica de Medicamentos , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Humanos , Neoplasias Hepáticas Experimentales/tratamiento farmacológico , Neoplasias Mamarias Animales/tratamiento farmacológico , Ratones , Ratones Endogámicos C3H , Ratones Desnudos , Trasplante de Neoplasias , Paclitaxel/uso terapéutico , Ácido Poliglutámico/uso terapéutico , Sarcoma Experimental/tratamiento farmacológico , Trasplante Heterólogo , Trasplante Homólogo , Células Tumorales CultivadasRESUMEN
Apoptosis induced by Fas (CD95) ligation is frequently lost during tumor progression; however, there is no direct evidence to support an association of Fas loss-of-function with metastatic tumor behavior. To determine whether Fas loss-of-function is critical for acquisition of the metastatic phenotype, we have compared the ability of Fas-sensitive K1735 murine melanomas to form spontaneous lung metastases in wild-type and Fas ligand-deficient mice. Fas-sensitive melanoma clones are highly tumorigenic but rarely metastatic in wild-type syngeneic mice. However, in Fas ligand-deficient mice, both the incidence and number of metastases are increased. These findings provide the first evidence that Fas-Fas ligand interactions can suppress metastasis and that tumor Fas loss-of-function may be causally linked to metastatic progression.
Asunto(s)
Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/secundario , Melanoma/inmunología , Melanoma/secundario , Glicoproteínas de Membrana/metabolismo , Receptor fas/metabolismo , Animales , Apoptosis , Proteína Ligando Fas , Ligandos , Neoplasias Pulmonares/patología , Melanoma/patología , Glicoproteínas de Membrana/deficiencia , Glicoproteínas de Membrana/genética , Ratones , Ratones Endogámicos C3H , Ratones Mutantes , Células Tumorales CultivadasRESUMEN
This paper proposes that international sexually transmitted disease (STD)/HIV prevention efforts might be enhanced by the application of social marketing principles. It first outlines the conceptual basis of social marketing approaches to health behaviour change generally and then explores key issues and opportunities for using these principles to improve current STD/HIV prevention efforts.
PIP: Social marketing is a research-driven, consumer-centered process used in the field of public health to change individuals' behavior. Social marketing differs from other health education strategies only in its approach, which is based upon commercial marketing techniques. In social marketing campaigns, social products such as condom use are viewed as commercial products and promoted using the same principles applied in the commercial sector. With consistent and long-term government commitment, social marketing programs have been highly effective. When used properly, social marketing-based public health interventions can help to prevent and control STDs and HIV. Health consumer behavior and focus, targeting and audience segmentation, social market research, the social marketing mix, and implications for social marketing STD/HIV prevention are discussed. Decreasing sexual partner change and making sex safe, improving access to effective STD treatment, and condom social marketing are then discussed as elements of social marketing to reduce sexual risk, followed by an examination of important policy considerations.
Asunto(s)
Infecciones por VIH/prevención & control , Comunicación Persuasiva , Conducta Sexual , Enfermedades de Transmisión Sexual/prevención & control , Condones/economía , Condones/provisión & distribución , Infecciones por VIH/epidemiología , Política de Salud , Accesibilidad a los Servicios de Salud , Humanos , Factores de Riesgo , Parejas Sexuales , Enfermedades de Transmisión Sexual/epidemiologíaRESUMEN
Over-expression of the epidermal growth factor receptor (EGFR) is a hallmark of numerous solid tumors, thus providing a means of selectively targeting therapeutic agents. Heparin-binding epidermal growth factor (HBEGF) binds to EGFRs with high affinity and to heparan sulfate proteoglycans, resulting in increased mitogenic potential compared to other EGF family members. We have investigated the feasibility of using HBEGF to selectively deliver a cytotoxic protein into EGFR-expressing tumor cells. Recombinant fusion proteins consisting of mature human HBEGF fused to the plant ribosome-inactivating protein saporin (SAP) were expressed in Escherichia coli. Purified HBEGF-SAP chimeras inhibited protein synthesis in a cell-free assay and competed with EGF for binding to receptors on intact cells. A construct with a 22-amino-acid flexible linker (L22) between the HBEGF and SAP moieties exhibited an affinity for the EGFR that was comparable to that of HBEGF. The sensitivity to HBEGF-L22-SAP was determined for a variety of human tumor cell lines, including the 60 cell lines comprising the National Cancer Institute Anticancer Drug Screen. HBEGF-L22-SAP was cytotoxic in vitro to a variety of EGFR-bearing cell lines and inhibited growth of EGFR-over-expressing human breast carcinoma cells in vivo. In contrast, the fusion protein had no effect on small-cell lung carcinoma cells, which are EGFR-deficient. Our results demonstrate that fusion proteins composed of HBEGF and SAP exhibit targeting specificity and cytotoxicity that may be of therapeutic value in treating a variety of EGFR-bearing malignancies.
Asunto(s)
Factor de Crecimiento Epidérmico/metabolismo , Receptores ErbB/metabolismo , Inmunotoxinas/metabolismo , N-Glicosil Hidrolasas , Proteínas de Plantas/metabolismo , Proteínas Recombinantes de Fusión/metabolismo , Estudios de Factibilidad , Vectores Genéticos , Factor de Crecimiento Similar a EGF de Unión a Heparina , Humanos , Péptidos y Proteínas de Señalización Intercelular , Proteínas Recombinantes de Fusión/farmacología , Proteínas Inactivadoras de Ribosomas Tipo 1 , Saporinas , Células Tumorales Cultivadas/metabolismoRESUMEN
An EGFR-expressing clone of the human ovarian cancer line 2774 was transfected with an antisense construct of EGFR to test how suppression of this gene modulates the malignant phenotype. Transfected clones were screened for EGFR expression by Western blot and FACS analysis. Anchorage-independent growth was used to assess the effect of reduced EGFR on the malignant behavior of the cells. Several transfected clones with decreased EGFR (40-50% reduction) were identified. A correlation was noted between reduced EGFR and decreased anchorage-independent growth, with the transfected clones losing the ability to grow in agarose and responsiveness to exogenous EGF. These results suggest that EGFR may be an important factor in the malignant behavior of this ovarian cancer cell line.
Asunto(s)
ADN sin Sentido , Receptores ErbB/genética , División Celular , Células Clonales , Receptores ErbB/biosíntesis , Femenino , Citometría de Flujo , Humanos , Cinética , Neoplasias Ováricas , Transcripción Genética , Transfección , Células Tumorales CultivadasRESUMEN
We recently found that overexpression of p185c-erbB2 in c-erbB2 transfected MDA-MB-435 breast cancer cells (435.eB transfectants) confers a 5-9-fold increase in Taxol resistance. To examine whether Taxol resistance is a common phenomenon in other c-erbB2 overexpressing breast cancer cell lines, we tested a panel of human breast cancer cell lines established from different patients and expressing pl85c-erbB2 at different levels for their sensitivity to Taxol and Taxotere, a synthetic taxoid. Higher expression of p185c-erbB2 in these breast cancer cell lines indeed correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fold that in c-erbB2-overexpressing 435.eB transfectants, demonstrating that these breast cancer cells are highly resistant to Taxol. Since mdr-1-encoded p-glycoprotein (p170mdr-1) has been implicated in Taxol resistance, we next examined the p170mdr-1 levels in these breast cancer cell lines that are highly resistant to Taxol. Higher levels of p170mdr-1 expression were found in several breast cancer cell lines that are highly resistant to Taxol. Since these same breast cancer cell lines also expressed higher levels of p185c-erbB2, we sought to determine the relative contribution of p185c-erbB2 and p170mdr-1 overexpression to Taxol resistance. We first specifically down-regulated cell surface p185c-erbB2 using anti-p185c-erbB2 monoclonal antibodies and assayed sensitivity of these cells to Taxol. We next specifically inactivated p170mdr-1 function using p170mdr-1 blockers (thioridazine or verapamil) and again assayed Taxol sensitivity. Both p185c-erbB2 down-regulation and p170mdr-1 blockade significantly sensitized the breast cancer cell lines to Taxol. The results indicate that overexpression of either p185c-erbB2 or p170mdr-1 renders human breast cancer cells resistant to Taxol. Furthermore, p185c-erbB2 synergizes with p170mdr-1 conferring higher degrees of Taxol resistance. Finally, combination therapy (down-regulation of p185c-erbB2 plus blocking p170mdr-1 plus administration of Taxol) may be beneficial to breast cancer patients whose tumors express high levels of both p185c-erbB2 and p170mdr-1.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Antineoplásicos Fitogénicos/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Resistencia a Antineoplásicos/fisiología , Paclitaxel/farmacología , Receptor ErbB-2/metabolismo , Taxoides , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Neoplasias de la Mama/genética , Neoplasias de la Mama/metabolismo , Docetaxel , Femenino , Expresión Génica , Humanos , Paclitaxel/análogos & derivados , Receptor ErbB-2/genética , Células Tumorales CultivadasRESUMEN
BACKGROUND: By the time patients are diagnosed with ovarian carcinoma, peritoneal dissemination of the tumor often has occurred. The progressive growth and spread of ovarian carcinoma depend, in part, on the formation of an adequate blood supply. We determined whether the expression of genes that regulate distinct steps in angiogenesis (i.e., the formation of new blood vessels) was associated with the pattern and progressive growth of human ovarian carcinomas implanted in the peritoneal cavity of nude mice. METHODS: Five different human ovarian carcinomas were injected individually into the peritoneal cavity of female NCr-nu/nu nude mice. The expression of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), interleukin 8 (IL-8), and collagenase type IV (MMP-2 [matrix metalloproteinase-2] and MMP-9) was determined by northern blot analysis, in situ hybridization of messenger RNA, and immunohistochemical analysis. Blood vessel distribution and density, macrophage infiltration pattern, and stromal reaction were determined by immunohistochemical analysis with specific antibodies. RESULTS: Three of the carcinomas produced both solid lesions and ascitic tumors, whereas the remaining two produced only solid lesions. Two of the carcinomas produced rapidly progressive disease, two produced slow disease, and one produced intermediate disease. The formation of ascites was directly associated with expression of VEGF/ VPF, and survival was inversely associated with expression of IL-8. In rapidly growing tumors, the number of blood vessels was high throughout the lesion; in contrast, in slow-growing tumors, most vessels (and infiltrating macrophages) were located at the periphery. CONCLUSIONS: The expression of various genes that regulate angiogenesis in human ovarian carcinomas is associated with the pattern of the disease and its progression. Therefore, targeting specific genes that regulate angiogenesis could offer new approaches to the treatment of ovarian cancer.
Asunto(s)
Regulación Neoplásica de la Expresión Génica , Neovascularización Patológica/genética , Neoplasias Ováricas/patología , Animales , Northern Blotting , Factores de Crecimiento Endotelial/biosíntesis , Femenino , Factor 2 de Crecimiento de Fibroblastos/biosíntesis , Gelatinasas/biosíntesis , Inmunohistoquímica , Hibridación in Situ , Interleucina-8/biosíntesis , Linfocinas/biosíntesis , Metaloproteinasa 2 de la Matriz , Metaloendopeptidasas/biosíntesis , Ratones , Ratones Desnudos , Sondas de Oligonucleótidos , Neoplasias Ováricas/genética , ARN Mensajero/análisis , ARN Neoplásico/análisis , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
A human cancer cell line was found to be heterogeneous for expression of the epidermal growth factor receptor (EGFR). Clones and variants of this cell line were separated on the basis of EGFR expression level, and those expressing high EGFR had different growth characteristics, in vitro and in vivo, than variants expressing low levels of EGFR. Karyotype analysis revealed that the heterogeneity was the result of mixing of two lines, the 2774 ovarian cancer cell line, and the SW620 colon cancer cell line. Our results reinforce the necessity for accurate identification of cell lines. Also, that measurement of gene expression on a single cell level, for example by flow cytometric analysis, can be more informative than measurements of cell lysates, since the initial indication of heterogeneity would not have been detected by northern or western blotting. The different cell types retained characteristic growth patterns when injected i.p. in nude mice, i.e. peritoneal carcinomatosis and ascites formation by the 2774 ovarian cancer cells, and liver metastasis and growth of discrete abdominal tumors by the SW620 colon cancer.
Asunto(s)
Neoplasias del Colon/genética , Neoplasias del Colon/patología , Receptores ErbB/genética , Neoplasias Ováricas/genética , Neoplasias Ováricas/patología , Animales , Ascitis , Técnicas de Cultivo de Célula/métodos , División Celular/efectos de los fármacos , Bandeo Cromosómico , Neoplasias del Colon/clasificación , Factor de Crecimiento Epidérmico/farmacología , Receptores ErbB/biosíntesis , Femenino , Citometría de Flujo , Variación Genética , Humanos , Cariotipificación , Cinética , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/secundario , Ratones , Ratones Desnudos , Neoplasias Ováricas/clasificación , Factor de Crecimiento Transformador alfa/farmacología , Trasplante HeterólogoRESUMEN
The ATF/CREB family of eukaryotic transcription factors contain the bZIP structural motif and mediate their transcriptional activities via heterodimerization with ATF and AP-1 family members. Quenching of CREB-associated proteins by a dominant-negative CREB (KCREB) that is mutated within its DNA-binding domain decreases radiation resistance of human melanoma cells. The purpose of this study was to determine the role of CREB in tumor growth and metastasis of human melanoma using KCREB. Highly metastatic MeWo human melanoma cells were transfected with the KCREB expression vector and subsequently analysed for changes in their tumorigenic and metastatic potential. Expression of KCREB in MeWo human cells decreased their tumorigenic and metastatic potential in nude mice compared with parental and control transfected cells. The KCREB-transfected cells displayed downregulation of 72 kDa collagenase type IV (MMP-2) mRNA expression and activity and decreased invasiveness through Matrigel-coated filters. Moreover, transcriptional activities mediated by the CAT gene driven by the MMP-2 promoter were decreased by 14-45-fold in KCREB-transfected cells. In addition, the cell-surface adhesion molecule MCAM/MUC18 that is involved in metastasis of human melanoma was downregulated in the KCREB-transfected cells. These data indicate that, through their transcriptional activities, CREB and its associated proteins play an important role in the acquisition of the metastatic phenotype of human melanoma cells.
Asunto(s)
Antígenos CD , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/metabolismo , Neoplasias Pulmonares/secundario , Melanoma/patología , Melanoma/secundario , Proteínas de Neoplasias/metabolismo , Moléculas de Adhesión de Célula Nerviosa , Animales , Antígeno CD146 , Cloranfenicol O-Acetiltransferasa/genética , Cloranfenicol O-Acetiltransferasa/metabolismo , Colágeno , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/genética , Regulación hacia Abajo , Combinación de Medicamentos , Gelatinasas/genética , Gelatinasas/metabolismo , Genes Reporteros , Humanos , Laminina , Masculino , Metaloproteinasa 2 de la Matriz , Melanoma/metabolismo , Glicoproteínas de Membrana/metabolismo , Metaloendopeptidasas/genética , Metaloendopeptidasas/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Invasividad Neoplásica , Proteínas de Neoplasias/genética , Trasplante de Neoplasias , Regiones Promotoras Genéticas , Proteoglicanos , Transfección , Células Tumorales CultivadasRESUMEN
The occurrence of breast cancer metastases is preferential to certain organs. Astrocytes may play an important role in the development of brain metastases, as these cells have been shown to respond to extracellular stimuli by producing many cytokines and growth factors that can modulate tumor cell proliferation, growth, and/or metastases. To test this hypothesis, we analyzed the responses of the human breast cancer cell line MDA-MB-435 and its metastatic sublines to astrocyte primary cultures from newborn rat cerebra. Astrocyte purity of the glial cell cultures was demonstrated by glial fibrillary acidic protein and rat neural antigen-2 (Ran-2) immunopositive staining. The 435-Br1 cell line, which was derived from a brain metastases in a nude mouse, showed increased adhesion to astrocytes and enhanced growth in vitro in the presence of media from Con A-stimulated astrocytes, relative to the parental MDA-MB-435 and the lung metastasis-derived variant 435-Lung2. Furthermore, the growth-stimulatory effect was partially reversed by anti-IL-6, anti-transforming growth factor beta (anti-TGF beta), and anti-IGF-I antibodies, indicating that these metastatic cells use exogenous cytokines as paracrine growth factors. In an attempt to elucidate the role of several biologic-response modifiers produced by astrocytes, we tested the responses of MDA-MB-435 cells to purified cytokines and growth factors. We found that the addition of recombinant human or mouse IL-6 produced a variety of responses in the different 435 metastatic variants. Furthermore, IL-6 receptor (IL-6R) expression was slightly increased in the 435-Br1 cells, and exogenous IL-6 rescued 435-Br1 cells from apoptosis in serum-depleted cultures. No apoptotic protective effect was observed in either MDA-MB-435 parental cells or 435-Lung2 cells. Thus, responses to exogenous IL-6 might determine the differences among these metastatic variants by extending cell survival of selected subpopulations, giving them the opportunity to respond to growth factors or other favorable conditions that might be present. These results suggest that cytokines produced by glial cells in vivo may contribute, in a paracrine manner, to the development of brain metastases by breast cancer cells.
Asunto(s)
Astrocitos/metabolismo , Neoplasias Encefálicas/secundario , Neoplasias de la Mama/metabolismo , Citocinas/metabolismo , Adulto , Animales , Animales Recién Nacidos , Apoptosis/efectos de los fármacos , Northern Blotting , Western Blotting , División Celular/efectos de los fármacos , Medios de Cultivo Condicionados/farmacología , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Factor I del Crecimiento Similar a la Insulina/farmacología , Interleucina-6/farmacología , Neoplasias Pulmonares/secundario , Ratones , Ratones Desnudos , Metástasis de la Neoplasia , Ratas , Ratas Wistar , Receptores de Interleucina-6/metabolismo , Proteínas Recombinantes/farmacología , Factor de Crecimiento Transformador beta/farmacología , Células Tumorales CultivadasRESUMEN
OBJECTIVES: Our purpose was to determine the molecular profile of advanced-stage transitional cell carcinoma in terms of immunostaining for p53, epidermal growth factor receptor and HER-2/neu, deoxyribonucleic acid index, and S-phase fraction and to analyze the prognostic significance of these markers. STUDY DESIGN: Archival paraffin-embedded tissue blocks from 29 advanced stage transitional cell carcinomas were obtained. Selected sections of the primary tumors were immunostained for p53, epidermal growth factor receptor, and HER-2/neu; deoxyribonucleic acid ploidy and S-phase fraction were determined with use of flow cytometry. Clinical information was abstracted from the medical records. Survival times were analyzed according to the life-table methods of Kaplan and Meier, and the statistical significance of the various factors was tested with the log-rank test. The proportional hazards model of Cox was used to identify prognostic factors. RESULTS: Positive immunostaining was observed for p53 in 13 cases (45%), for epidermal growth factor receptor in 14 cases (50%), and for HER-2/neu in 19 cases (65%). Tumors were diploid in 16 cases (55%) and aneuploid in 13 (45%). The S-phase fraction was < or = 15% (mean) in 13 cases (45%) and > 15% in 16 cases (55%). The median survival for the entire group was 52 months. None of the above variables had a significant effect on survival time. CONCLUSION: Neither immunostaining for p53, epidermal growth factor receptor, and HER-2/neu nor deoxyribonucleic acid ploidy nor S-phase fraction allowed us to distinguish transitional cell carcinoma from other more common epithelial ovarian cancers. In addition, no prognostic significance was associated with these biomarkers. A study of larger numbers of cases may be more elucidative.
Asunto(s)
Biomarcadores de Tumor/análisis , Carcinoma de Células Transicionales/química , ADN de Neoplasias/análisis , Receptores ErbB/análisis , Neoplasias Ováricas/química , Receptor ErbB-2/análisis , Proteína p53 Supresora de Tumor/análisis , Adulto , Anciano , Carcinoma de Células Transicionales/patología , Ciclo Celular/fisiología , Femenino , Citometría de Flujo , Humanos , Inmunohistoquímica , Tablas de Vida , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Ováricas/patología , Estudios Retrospectivos , Fase SAsunto(s)
Antioxidantes/administración & dosificación , Enfermedades Cardiovasculares/prevención & control , Vitaminas/administración & dosificación , beta Caroteno/administración & dosificación , Antioxidantes/efectos adversos , Antioxidantes/farmacocinética , Ácido Ascórbico/administración & dosificación , Ácido Ascórbico/efectos adversos , Ácido Ascórbico/farmacocinética , Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/mortalidad , Humanos , Necesidades Nutricionales , Ensayos Clínicos Controlados Aleatorios como Asunto , Vitamina A/administración & dosificación , Vitamina A/efectos adversos , Vitamina A/farmacocinética , Vitaminas/efectos adversos , Vitaminas/farmacocinética , beta Caroteno/efectos adversos , beta Caroteno/farmacocinéticaAsunto(s)
Enfermedades de los Gatos/diagnóstico , Cuerpos Extraños/veterinaria , Cavidad Nasal , Estornudo , Amoxicilina/uso terapéutico , Animales , Antibacterianos/uso terapéutico , Enfermedades de los Gatos/terapia , Gatos , Ácido Clavulánico , Ácidos Clavulánicos/uso terapéutico , Quimioterapia Combinada/uso terapéutico , Femenino , Cuerpos Extraños/diagnóstico , Cuerpos Extraños/terapia , Penicilinas/uso terapéuticoRESUMEN
The introduction of adenovirus 5 E1A into the SKOV3ip1 ovarian cancer cell line was shown previously to suppress HER2/neu expression and reduce the malignant potential of these cells (Yu et al., Cancer Res., 53: 891-898, 1993). In this report, we show that reduction of p185 in cells stably expressing E1A protein was coincident with increased sensitivity to cytotoxic agents. The LD50 of cisplatin was reduced 6-fold, and the LD50 of paclitaxel and doxorubicin was reduced 10-fold in E1A-expressing cells compared with control cells. The growth of SKOV3ip1 and control cells was unchanged in the presence of 150 ng/ml of tumor necrosis factor-alpha, whereas the growth of E1A-expressing cells was reduced by 30 to 40%. When we used a physiologically obtainable concentration of paclitaxel (0.5 microM), DNA laddering consistent with apoptotic cell death was seen after a 24-h exposure in the E1A-expressing cells, whereas laddering and DNA fragmentation were only detected in DNA from control cells after longer exposure (48 h) at a 20-fold higher concentration of paclitaxel. The SKOV3ip1 cells do not express p53 protein; hence, the induction of apoptosis by paclitaxel is through a p53-independent pathway. Despite their diverse mechanisms of action, the cytotoxic effects of cisplatin, doxorubicin, paclitaxel, and tumor necrosis factor-alpha were enhanced by the expression of E1A proteins in the SKOV3ip1 ovarian cancer cells. This suggests that these agents share a common final pathway of cell killing, which may represent a potential therapeutic target in resistant ovarian cancers.